Laparoscopic Retroperitoneal Lymph-Node Dissection in the Management of Clinical Stage I and II Testicular Cancer
Authors:
- 1 July 2005
- journal article
- research article
- Published by SAGE Publications in Journal of Endourology
- Vol. 19 (6) , 683-692
Abstract
Background and Purpose: Laparoscopic retroperitoneal lymph-node dissection (RPLND) has been advocated for and utilized in the management of testicular cancer. In this overview, we present our technique and results in comparison with the worldwide experience with laparoscopic RPLND in the management of clinical stage I and II cancers. Patients and Methods: Over the last 13 years, 162 patients with testicular cancer clinical stage I (N = 103) or II (N = 43 IIB, 16 IIC) underwent laparoscopic RPLND. All intraoperative and postoperative data were evaluated, as well as the worldwide experience with the procedure. With a mean follow-up of 62 months (range 6–113 months) for clinical stage I and 53 months (range 10–89 months) for clinical stage II, oncologic efficiency was evaluated. Results: The procedure was feasible even after chemotherapy, with only three conversions to open RPLND in clinical stage I. The mean operative time was 217, 216, and 281 minutes for clinical stages I, IIB, and IIC, respectively. The mean blood loss was 144 mL and 165 mL for clinical stage I and II, respectively. The hospital stays were 3.6 and 3.8 days, respectively. During follow-up, we had two retroperitoneal relapses (1.2%) and four distant relapses (2.5%). Conclusion: Laparoscopic RPLND has demonstrated its surgical and oncologic efficacy. The morbidity and the complication rate are low. Recurrence rates are comparable to those of open surgery. Laparoscopic RPLND is safe, with less postoperative morbidity, quicker convalescence, better cosmetic results, and a diagnostic accuracy equal that of the open technique.Keywords
This publication has 29 references indexed in Scilit:
- Laparoscopic RPLND for clinical stage I nonseminomatous germ cell testicular cancer: current statusUrologic Oncology: Seminars and Original Investigations, 2004
- Risk Factors for Relapse in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: Results of the German Testicular Cancer Study Group TrialJournal of Clinical Oncology, 2003
- Laparoscopic Versus Open Retroperitoneal Lymph Node Dissection: a Cost AnalysisJournal of Urology, 2002
- SURVEILLANCE CAN BE THE STANDARD OF CARE FOR STAGE I NONSEMINOMATOUS TESTICULAR TUMORS AND EVEN HIGH RISK PATIENTSJournal of Urology, 2001
- EXTRAPERITONEAL LAPAROSCOPIC PARA-AORTIC LYMPH NODE DISSECTION FOR EARLY STAGE NONSEMINOMATOUS GERM CELL TUMORS OF THE TESTIS WITH INTRODUCTION OF A NERVE SPARING TECHNIQUE: DESCRIPTION AND RESULTSJournal of Urology, 2001
- Long–Term Experience with Laparoscopic Retroperitoneal Lymph Node Dissection in the Management of Low–Stage Testis CancerEuropean Urology, 2000
- CLINICAL STAGE I TESTIS CANCERJournal of Urology, 1998
- Retroperitoneal Lymphadenectomy for Clinical Stage I Nonseminomatous Testicular Tumor: Laparoscopy Versus Open Surgery and Impact of Learning CurveJournal of Urology, 1996
- A Surveillance Study of Clinical Stage I Nonseminomatous Germ Cell Tumors of the TestisJournal of Urology, 1995
- Immediate Adjuvant Chemotherapy versus Observation with Treatment at Relapse in Pathological Stage II Testicular CancerNew England Journal of Medicine, 1987